Allergy Immunotherapy Advances: HDM Market Analysis

DelveInsight’s “Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Multiple System Atrophy, historical and forecasted epidemiology as well as the Multiple System Atrophy market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Multiple System Atrophy Market with DelveInsight’s In-Depth Report @ Multiple System Atrophy Market Size

Key Takeaways from the Multiple System Atrophy Market Report

• In March 2026, Lundbeck announced ahead-of-schedule completion of patient randomization in the Phase III MASCOT trial of amlenetug for MSA, with results expected in Q3 2027 and potential launch in Q1 2029.
• In December 2025, Lundbeck announced it will showcase the design of its Phase 3 MASCOT trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders. The trial evaluates amlenetug, an investigational monoclonal antibody targeting alpha-synuclein, for the treatment of Multiple System Atrophy (MSA). MSA is a rare, aggressive neurodegenerative disorder with no current disease-modifying treatments. The MASCOT study aims to determine if amlenetug can slow disease progression by preventing the aggregation of toxic proteins in the brain. This presentation will provide the medical community with key insights into the study’s methodology and its potential impact on MSA patients.
• In December 2025,Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has completed enrollment for its Phase 1 clinical trial of AB-1005 for Multiple System Atrophy-Parkinsonian type (MSA-P). AB-1005 is an investigational gene therapy that uses an AAV2 vector to deliver the GDNF gene directly to the brain. This approach is intended to support the survival of neurons and potentially slow the progression of the disease. The study focuses on the safety and tolerability of the surgical delivery method. This milestone is a critical step in determining if gene therapy can offer a neuroprotective benefit for patients with this rapidly progressing condition.
• In December 2025, Teva Pharmaceutical Industries announced that the U.S. FDA has granted Fast Track Designation to emrusolmin for the treatment of Multiple System Atrophy (MSA). Emrusolmin is an oral small molecule designed to inhibit the aggregation of alpha-synuclein, a key driver of MSA pathology. Fast Track status is intended to expedite the development and review of drugs for serious conditions with unmet medical needs. This designation allows Teva to have more frequent interactions with the FDA and potentially qualify for Priority Review. The news marks a significant advancement in the effort to bring a disease-modifying therapy to the MSA community.
• In September 2025, Teva Pharmaceutical (NYSE:TEVA) announced that its investigational MSA treatment, emrusolmin, received Fast Track designation from the U.S. FDA. The drug is currently in Phase 2 development for Multiple System Atrophy.
• In August 2025, Tiziana Life Sciences received FDA clearance of its IND for a Phase 2a trial of intranasal foralumab in patients with Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved therapies. The six-month open-label study will evaluate microglial activation, clinical outcomes, and safety of the fully human anti-CD3 monoclonal antibody delivered via nasal spray.
• In July 2025, NKGen Biotech received FDA authorization for an Expanded Access Program (EAP) to use its NK cell therapy, troculeucel, in multiple neurodegenerative diseases—including Alzheimer’s, Parkinson’s, ALS, MSA, PSP, FTD, CBD, MS, and Lewy Body Dementia—beyond its current Phase 2a trial in moderate-stage Alzheimer’s disease.
• In May 2025, Alterity Therapeutics announced that the FDA has granted Fast Track designation for ATH434, its investigational treatment for Multiple System Atrophy (MSA). This designation aims to expedite the development and review of ATH434, recognizing its potential to address the significant unmet need in MSA, a condition currently without an approved therapy.
• In February 2025, Alterity Therapeutics’ ATH434 showed promising Phase 2 results in a randomized, double-blind trial for early-stage multiple system atrophy (Multiple System Atrophy). The treatment, particularly at a 50 mg dose, was well-tolerated and demonstrated both clinical and biomarker-based benefits.
• In 2025, the diagnosed prevalent cases of MSA are predicted to be approximately 72,000 in the leading markets (the United States, EU4, the United Kingdom, and Japan), projected to increase through 2036.
• According to DelveInsight’s analysis, in 2025, the US had the highest number of diagnosed prevalent cases of MSA among the 7MM, with more than 43,000 cases, followed by Japan with nearly 17,000 cases.
• MSA is divided into six stages: Stage 0, Stage 1, Stage 2, Stage 3, Stage 4, and Stage 5. In 2025, Stage 3 had the highest diagnosed prevalence, with around 4,000 cases reported in EU4 and the UK.
• In the UK, the 70 years and above age group reported the highest number of MSA around 1,200 cases in 2025, surpassing other age groups such as 50–59 and 60–69, with projections indicating an increase by 2036.
• The leading Multiple System Atrophy Companies such as Teva Pharmaceutical, MODAG GmbH, Theravance Biopharma, H. Lundbeck A/S, Genmab, Deciphera Pharmaceuticals, ONO PHARMA, Asklepios BioPharmaceutical, Brain Neurotherapy Bio, Inc., Ionis Pharmaceuticals, Inc., Biogen, Alterity Therapeutics, and others.
• Promising Multiple System Atrophy Therapies such as Amlenetug (Lu AF82422), Ampreloxetine (TD-9855), Emrusolmin (TEV-56286, Anle-138b), TAK-341/MEDI1341, ATH434, ONO-2808, and others.

Stay ahead in the Multiple System Atrophy Therapeutics Market with DelveInsight’s Strategic Report @ Multiple System Atrophy Market Outlook

Multiple System Atrophy Epidemiology Segmentation in the 7MM

• Diagnosed Prevalent Cases of Multiple System Atrophy
• Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy
• Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy
• Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy
• Stage-specific Diagnosed Prevalent Cases of Multiple System Atrophy
• nOH Symptomatic Cases of Multiple System Atrophy

Download the report to understand which factors are driving Multiple System Atrophy Epidemiology trends @ Multiple System Atrophy Prevalence

Marketed Multiple System Atrophy Therapies Currently, there are no approved disease-modifying therapies to slow Multiple System Atrophy’s neurodegeneration. Symptom management options include levodopa, amantadine, droxidopa, adrenergic receptor agonists, and various off-label therapies that provide relief and help patients cope with the disease’s effects. Northera (droxidopa) is commonly prescribed for neurogenic orthostatic hypotension (nOH), a common Multiple System Atrophy symptom. Approved in 2014, northera addresses nOH but lost market exclusivity in 2021.

Emerging Multiple System Atrophy Therapies

• Amlenetug (Lu AF82422): H. Lundbeck A/S/Genmab Amlenetug (Lu AF82422) is a human IgG1 monoclonal antibody targeting extracellular α-synuclein to block aggregation and enhance microglial clearance, developed by Lundbeck in collaboration with Genmab. In March 2026, Lundbeck announced ahead-of-schedule completion of patient randomization in the Phase III MASCOT trial of amlenetug for MSA, with results expected in Q3 2027 and potential launch in Q1 2029.
• Ampreloxetine (TD-9855): Theravance Biopharma Ampreloxetine is a norepinephrine reuptake inhibitor (NRI) and serotonin (5-HT) uptake inhibitor for symptomatic neurogenic orthostatic hypotension in Multiple System Atrophy. It is currently in Phase III trials with ODD status.
• Emrusolmin (TEV-56286, Anle-138b): Teva Pharmaceutical/MODAG GmbH Emrusolmin, also known as anle138b, is a small molecule designed to specifically target toxic oligomeric structures of alpha-synuclein, the primary aggregating protein involved in neurodegenerative disorders. By binding to these toxic oligomers, anle138b dissolves them and prevents the formation of new ones, addressing the underlying cause of the disease. It is orally administered, crosses the blood-brain barrier, and received orphan drug designation for Multiple System Atrophy. In December 2025, Teva Pharmaceutical Industries announced that the U.S. FDA has granted Fast Track Designation to emrusolmin for the treatment of Multiple System Atrophy.

To know more about Multiple System Atrophy treatment guidelines, visit @ Multiple System Atrophy Treatment Market Landscape

Multiple System Atrophy Therapies and Companies

• Amlenetug (Lu AF82422): H. Lundbeck A/S/Genmab
• Ampreloxetine (TD-9855): Theravance Biopharma
• Emrusolmin (TEV-56286, Anle-138b): Teva Pharmaceutical/MODAG GmbH
• ATH434: Alterity Therapeutics
• TAK-341/MEDI1341: AstraZeneca/Takeda Pharma
• ONO-2808: Deciphera Pharmaceuticals/ONO PHARMA
• AB-1005: Asklepios BioPharmaceutical

Multiple System Atrophy Market Dynamics The Multiple System Atrophy market dynamics have undergone significant changes over the years. The aging population is a significant driver, as MSA typically begins after age 30 and prevalence increases with age. The growing patient pool creates demand for effective therapies. With limited FDA-approved disease-modifying treatments currently available, the field presents a significant opportunity for innovation. Existing options provide limited relief, highlighting a clear pathway for novel, targeted therapies to transform patient outcomes. The rapid progression, severe morbidity, and shortened life expectancy of the disease lead to poor patient outcomes, profoundly affecting the quality of life for individuals and their caregivers. Emerging therapies, such as monoclonal antibodies and small molecules, including amlenetug, ampreloxetine, and ATH434, among others offer advanced immune-modulating approaches with potential to reshape the treatment landscape.

Learn more about the emerging therapies for Multiple System Atrophy @ Drugs for Multiple System Atrophy Treatment

Scope of the Multiple System Atrophy Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Multiple System Atrophy Companies- Teva Pharmaceutical, MODAG GmbH, Theravance Biopharma, H. Lundbeck A/S, Genmab, Deciphera Pharmaceuticals, ONO PHARMA, Asklepios BioPharmaceutical, Brain Neurotherapy Bio, Inc., Ionis Pharmaceuticals, Inc., Biogen, Alterity Therapeutics, and others
• Multiple System Atrophy Therapies- Amlenetug (Lu AF82422), Ampreloxetine (TD-9855), Emrusolmin (TEV-56286, Anle-138b), TAK-341/MEDI1341, ATH434, ONO-2808, and others
• Multiple System Atrophy Unmet Needs, KOL’s views, Analyst’s views, Multiple System Atrophy Market Access and Reimbursement

Table of Content

1. Key Insights
2. Report Introduction
3. MSA Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Key Events
6. Executive Summary
7. Disease Background and Overview: MSA
8. Patient Journey
9. Epidemiology and Patient Population
10. Emerging Drugs
11. MSA: Seven Major Market Analysis
12. KOL Opinion Leaders’ Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Gene Therapy Market Insights and Market Forecast-2032” report delivers an in-depth understanding of the Gene Therapy, historical and forecasted market trends as well as the Gene Therapy market dynamics in North America, Europe, Asia-Pacific, and Rest of the World.

Discover Key Insights into the Gene Therapy Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/report-store/gene-therapy-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Key Takeaways from the Gene Therapy Market Report

• In November 2024, PTC Therapeutics announced FDA approval with the brand name KEBILIDI™ (eladocagene exuparvovec-tneq), indicated for the treatment of children and adults with AADC deficiency.
• In June 2023, Sarepta Therapeutics, Inc. announced that the U.S. FDA granted accelerated approval for ELEVIDYS, a gene therapy for ambulatory pediatric patients aged 4 to 5 years with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.
• The global gene therapy market was valued at USD 8,570.28 million in 2024, growing at a CAGR of 19.25% during the forecast period from 2025 to 2032 to reach USD 34,933.71 million by 2032.
• According to data from the Haemophilia Foundation Australia (2024), over 7,400 individuals in Australia were diagnosed with bleeding disorders. Globally, haemophilia affected approximately 1 in 6,000–10,000 males, with an estimated 830,895 individuals worldwide having haemophilia, including about 282,266 with severe cases.
• According to the Centre for Disease Control and Prevention (2024), in the United States, approximately 33,000 males were estimated to be living with hemophilia, while about 1 in every 5,000 males aged 5-9 years had Duchenne or Becker muscular dystrophy (DBMD).
• According to the Haemophilia Foundation Australia (2024), Von Willebrand disease (VWD) was diagnosed in over 2,500 people in Australia, though many cases were believed to be undiagnosed.
• North America is expected to account for the highest proportion of the gene therapy market in 2024, with advanced healthcare infrastructure, strong research and development capabilities, and substantial financial investments in innovative biopharmaceuticals.
• The leading Gene Therapy Companies such as F. Hoffmann-La Roche Ltd., Novartis AG, Ferring B.V., bluebird bio, Inc., CSL, Ultragenyx Pharmaceutical Inc., PTC Therapeutics, BioMarin, Biogen, Prevail Therapeutics, Sarepta Therapeutics, Inc., Kriya Therapeutics, Affinia Therapeutics, Caribou Biosciences, Pfizer Inc., and others.
• Promising Gene Therapies such as Valoctocogene Roxaparvovec, Upstaza™ (eladocagene exuparvovec), BEQVEZ™ (fidanacogene elaparvovec-dzkt), KEBILIDI™ (eladocagene exuparvovec-tneq), ELEVIDYS (delandistrogene moxeparvovec-rokl), Luxturna, giroctocogene fitelparvovec, Roctavian, Hemgenix, and others.

Stay ahead in the Gene Therapy Market with DelveInsight’s Strategic Report @ https://www.delveinsight.com/report-store/gene-therapy-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Gene Therapy Market Segmentation

• Gene Therapy Market by Vector Type (Viral and Non-Viral)
• Gene Therapy Market by Delivery Type (Ex Vivo and In Vivo)
• Gene Therapy Market by Indication (Neurological, Oncological, Hematological, Ophthalmological, and Others)
• Gene Therapy Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Download the report to understand which factors are driving Gene Therapy Market trends @ https://www.delveinsight.com/report-store/gene-therapy-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Marketed Gene Therapies

• Upstaza™ (eladocagene exuparvovec): PTC Therapeutics, Inc. In July 2022, PTC Therapeutics, Inc. announced that the European Commission granted marketing authorization for Upstaza™. Upstaza became the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first gene therapy directly infused into the brain to reach the market. Approved for patients aged 18 months and older, Upstaza is an AAV2 viral-based gene therapy containing the human DDC gene delivered via recombinant technology. In November 2024, PTC Therapeutics announced FDA approval with the brand name KEBILIDI™ (eladocagene exuparvovec-tneq), indicated for the treatment of children and adults with AADC deficiency.
• BEQVEZ™ (fidanacogene elaparvovec-dzkt): Pfizer Inc. In April 2024, Pfizer Inc. announced the FDA approval of BEQVEZ™, a one-time gene therapy for adults with hemophilia B. BEQVEZ represents a significant advancement in hemophilia B treatment by introducing functional genes to restore clotting factor production.
• ELEVIDYS (delandistrogene moxeparvovec-rokl): Sarepta Therapeutics, Inc. In June 2023, Sarepta Therapeutics, Inc. announced that the U.S. FDA granted accelerated approval for ELEVIDYS, a gene therapy for ambulatory pediatric patients aged 4 to 5 years with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.
• Luxturna: Various AAV-based therapies like Luxturna are being used to treat genetic forms of retinal disorders, including Leber congenital amaurosis, representing a breakthrough in treating inherited blindness.

Emerging Gene Therapies

• Valoctocogene Roxaparvovec: Various AAV vectors are being used to deliver clotting factor genes to treat hemophilia A and B. Therapies like Valoctocogene Roxaparvovec have been developed using AAV vectors to treat hemophilic patients, offering the potential to reduce or eliminate the need for factor replacement therapy.
• giroctocogene fitelparvovec: Pfizer Inc. In July 2024, Pfizer Inc. announced positive topline results from the Phase 3 AFFINE study, evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. These advancements reflect the broader interest and investment in gene therapy.

To know more about Gene Therapy treatment landscape, visit @ https://www.delveinsight.com/report-store/gene-therapy-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Gene Therapy Companies

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Ferring B.V.
• bluebird bio, Inc.
• CSL
• Ultragenyx Pharmaceutical Inc.
• PTC Therapeutics
• BioMarin
• Biogen
• Prevail Therapeutics
• Sarepta Therapeutics, Inc.
• Kriya Therapeutics
• Affinia Therapeutics
• Caribou Biosciences
• Pfizer Inc.

Gene Therapy Market Dynamics The gene therapy market dynamics have undergone significant changes over the years. The rising prevalence of genetic and rare diseases has driven demand for innovative treatments, positioning gene therapy as a promising solution. This demand is supported by the rapid expansion of the gene therapy pipeline, which includes numerous clinical trials and advanced therapies targeting conditions previously considered untreatable. Additionally, strategic activities such as mergers, acquisitions, and partnerships among key players have accelerated research, development, and commercialization efforts, collectively fostering innovation and boosting the overall market for gene therapy globally. Viral vectors, such as Adeno-Associated Viruses (AAV), Lentiviruses, and Adenoviruses, are used extensively because of their innate ability to enter cells and introduce genetic material with precision and efficiency.

Learn more about Gene Therapies @ https://www.delveinsight.com/report-store/gene-therapy-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Scope of the Gene Therapy Market Report

• Coverage- Global (North America, Europe, Asia-Pacific, and Rest of the World)
• Study Period- 2020-2032
• Gene Therapy Companies- F. Hoffmann-La Roche Ltd., Novartis AG, Ferring B.V., bluebird bio, Inc., CSL, Ultragenyx Pharmaceutical Inc., PTC Therapeutics, BioMarin, Biogen, Prevail Therapeutics, Sarepta Therapeutics, Inc., Kriya Therapeutics, Affinia Therapeutics, Caribou Biosciences, Pfizer Inc., and others
• Gene Therapies- Valoctocogene Roxaparvovec, Upstaza™, BEQVEZ™, KEBILIDI™, ELEVIDYS, Luxturna, giroctocogene fitelparvovec, Roctavian, Hemgenix, and others
• Gene Therapy Market Drivers, Market Barriers, Market Opportunities

Table of Content

1. Gene Therapy Market Report Introduction
2. Gene Therapy Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Gene Therapy Market Key Factors Analysis
6. Gene Therapy Market Porter’s Five Forces Analysis
7. Gene Therapy Market Assessment
8. Gene Therapy Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com 

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

Discover Key Insights into the Fabry Disease Market with DelveInsight’s In-Depth Report @ Fabry Disease Market Size

Key Takeaways from the Fabry Disease Market Report

• In January 2026, Idorsia Pharmaceuticals presented Phase III MODIFY trial data showing a possible signal in patients with reduced baseline kidney function; however, no statistically significant renal benefit was observed with lucerastat in adults with Fabry disease. The regulatory pathway is expected to be discussed with the US FDA.
• In Jan 2026, the FDA approved an expanded label for Cerezyme (imiglucerase) to include non-central nervous system manifestations of Type 3 Gaucher disease. While it does not treat the neurological symptoms, this expansion—based on real-world evidence from the International Collaborative Gaucher Group—allows for a broader global standard of care for the systemic symptoms of GD3.
• In December 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion. This landmark deal consolidates BioMarin’s leadership in rare diseases, adding Galafold (for Fabry disease) and the Pombiliti + Opfolda combination (for Pompe disease) to its portfolio. The acquisition is expected to accelerate BioMarin’s revenue growth by leveraging its global commercial footprint across 80 countries.
• In November 2025, Sangamo Therapeutics announced that the US FDA accepted its request for a rolling BLA review for ST-920, and in December 2025, the company initiated the rolling submission seeking accelerated approval for the treatment of adults with Fabry disease.
• In November 2025, Chiesi Global Rare Diseases and Protalix BioTherapeutics requested a re-examination from the EMA regarding a negative opinion on a new dosing regimen for Elfabrio. The companies are seeking approval for a 2 mg/kg every four weeks option, providing more flexibility for Fabry disease patients who currently rely on bi-weekly infusions.
• According to DelveInsight’s assessment, in 2025, the 7MM had approximately 18,000 diagnosed prevalent cases of Fabry disease. Increased newborn screening and genetic testing are expected to expand this pool, reaching around 58K by 2036, especially in late-onset variants that often remain undiagnosed.
• In the 7MM, the US accounted for the highest number of diagnosed prevalent cases of Fabry disease, with nearly 9,400 cases in 2025.
• In 2025, EU4 and the UK accounted for nearly 6,900 diagnosed prevalent cases of Fabry disease.
• In 2025, there were ~700 and ~1,000 diagnosed prevalent cases among male and females respectively, in Japan.
• In the US, the 10–19 years of age group had the highest number of cases, while the 40–49 years of age group accounted for the least number of cases.
• Fabry disease affects 1 in 1,000 to 40,000 people globally, with late-onset cases being more common. Adults with Fabry disease often experience progressive organ damage, leading to significant morbidity and mortality, typically by the fourth or fifth decade of life.
• The leading Fabry Disease Companies such as Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma, Exegenesis Bio, Idorsia Pharmaceuticals, 4D Molecular Therapeutics, AceLink Therapeutics, and others.
• Promising Fabry Disease Therapies such as Venglustat, Isaralgagene civaparvovec (ST-920), Lucerastat, AMT-191, 4D-310, AL01211, EXG110, and others.

Stay ahead in the Fabry Disease Therapeutics Market with DelveInsight’s Strategic Report @ Fabry Disease Market Outlook

Fabry Disease Epidemiology Segmentation in the 7MM

• Total Fabry Disease Diagnosed Prevalent Cases
• Fabry Disease Gender-specific Diagnosed Prevalent Cases
• Fabry Disease Age-specific Diagnosed Prevalent Cases
• Fabry Disease Phenotype-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Fabry Disease Epidemiology trends @ Fabry Disease Prevalence

Marketed Fabry Disease Therapies

• FABRAZYME: Sanofi (Genzyme) FABRAZYME is FDA-approved for patients aged ≥2 years, making it the primary enzyme replacement therapy (ERT) for Fabry disease in the US. Developed by Sanofi-Genzyme, it is an ERT given via IV infusion every two weeks. Approved by the FDA in 2003, it is available in over 70 countries and remains a cornerstone of Fabry disease treatment as the first FDA-approved ERT.
• REPLAGAL: Takeda Pharmaceuticals REPLAGAL (agalsidase alfa), developed by Shire (now Takeda), was approved in Europe (2001) and Japan (2007) for patients aged 7+ years but is unavailable in the US. REPLAGAL has retained a strong foothold in the European and Japanese markets for over two decades, largely due to its well-documented efficacy and the absence of biosimilar competition.
• GALAFOLD (migalastat): Amicus Therapeutics GALAFOLD is an oral pharmacological chaperone of α-Gal A for the treatment of Fabry disease in adults who have amenable galactosidase-α gene variants. The orally administered therapeutic candidate acts as a pharmacological chaperone designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of the lysosomal enzyme α-Gal A. GALAFOLD is the first FDA-approved oral chaperone therapy for Fabry disease (2018), effective for specific GLA mutations, benefiting 35–50% of patients.
• ELFABRIO (pegunigalsidase alfa): CHIESI Farmaceutici and Protalix Biotherapeutics ELFABRIO is a pegylated ERT for Fabry disease, approved for adult Fabry patients in the EU and US. It currently follows a bi-weekly regimen, with efforts underway for monthly dosing approval (EMA validation). PRX-102 is a plant cell culture-expressed and chemically modified stabilized version of the recombinant α Gal A enzyme with unique pharmacokinetic parameters.

Emerging Fabry Disease Therapies

• Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics ST-920 is a liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase-A that is delivered through a single dose IV infusion. The drug aims to deliver a working copy of the galactosidase-α gene to the liver so that liver cells can start producing functional alpha-galactosidase-A. ST-920 has the potential as a one-time, durable treatment option for Fabry disease. ST-920 is the potential gene therapy in the development of Fabry disease, with its expected approval by Q2 2026 in the US.
• Venglustat: Sanofi (Genzyme) Venglustat is a novel, oral investigational therapy that has the potential to slow the progression of certain diseases by inhibiting abnormal glycosphingolipids accumulation. The drug inhibits the enzymatic conversion of ceramide to glucosylceramide, reducing available substrate for the synthesis of more complex glycosphingolipids. It is getting evaluated in Phase III for Fabry disease, with expected approval by 2027 in the US.

To know more about Fabry Disease treatment guidelines, visit @ Fabry Disease Treatment Market Landscape

Fabry Disease Therapies and Companies

• Venglustat: Sanofi (Genzyme)
• Lucerastat: Idorsia Pharmaceuticals
• Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics
• AMT-191: UniQure Biopharma
• 4D-310: 4D Molecular Therapeutics
• AL01211: AceLink Therapeutics
• EXG110: Exegenesis Bio

Fabry Disease Market Dynamics The Fabry disease market dynamics have undergone significant changes over the years. The aging population and improved diagnostic techniques, particularly newborn screening, have expanded the patient pool. Advancements in medical research and development have brought new treatments including enzyme replacement therapies, chaperone therapy, and promising gene therapies to the market. The transition toward one-time therapies (gene therapy) has the potential to disrupt the recurring ERT model. However, reimbursement challenges and durability data will determine long-term market penetration. Growing awareness and improved diagnostic techniques are crucial for early detection and better patient outcomes.

Learn more about the FDA-approved drugs for Fabry Disease @ Drugs for Fabry Disease Treatment

Scope of the Fabry Disease Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Fabry Disease Companies- Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma, Exegenesis Bio, Idorsia Pharmaceuticals, 4D Molecular Therapeutics, AceLink Therapeutics, and others
• Fabry Disease Therapies- Venglustat, Isaralgagene civaparvovec (ST-920), Lucerastat, AMT-191, 4D-310, AL01211, EXG110, and others
• Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

Table of Content

• Key Insights
• Report Introduction
• Executive Summary
• Key Events
• Epidemiology and Market Forecast Methodology of Fabry Disease
• Fabry Disease Market Overview at a Glance
• Disease Background and Overview
• Epidemiology and Patient Population of Fabry Disease in the 7MM
• Patient Journey of Fabry Disease
• Marketed Therapies of Fabry Disease
• Emerging Therapies of Fabry Disease
• Fabry Disease: 7MM Analysis
• Unmet Needs of Fabry Disease
• SWOT Analysis of Fabry Disease
• KOL Views of Fabry Disease
• Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

The Ductal Carcinoma in Situ market is anticipated to grow with a significant CAGR during the forecast period, driven by rising awareness of early-stage breast cancer, advancements in precision diagnostics, and increasing healthcare spending. Additionally, the development of emerging targeted therapies and novel treatment approaches is expected to significantly transform the Ductal Carcinoma in Situ market landscape and treatment dynamics.

DelveInsight’s “Ductal Carcinoma in Situ Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Ductal Carcinoma in Situ, historical and forecasted epidemiology as well as the Ductal Carcinoma in Situ market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ductal Carcinoma in Situ market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Ductal Carcinoma in Situ market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ductal Carcinoma in Situ Market Forecast

Some of the key facts of the Ductal Carcinoma in Situ Market Report:

• The Ductal Carcinoma in Situ market size is anticipated to reach USD XX Million by 2034, growing with a significant CAGR during the study period (2020-2034).
• In January 2025, Prelude Corporation (PreludeDx®) announced that the FDA granted Breakthrough Device designation for its DCISionRT® test, a precision diagnostic for early-stage breast cancer. This designation recognizes the test’s potential to provide more effective treatment decisions for patients with ductal carcinoma in situ, representing a significant advancement in personalized breast cancer care.
• Key Ductal Carcinoma in Situ Companies: Atossa Therapeutics Inc, F. Hoffmann-La Roche Ltd, ImmunoRestoration Inc, SELLAS Life Sciences Group Inc, University of Pittsburgh, Marker Therapeutics Inc, and others
• Key Ductal Carcinoma in Situ Therapies: Multiple emerging therapies in late-stage and mid-stage development focused on novel approaches to treat and improve disease management
• The Ductal Carcinoma in Situ epidemiology provides comprehensive patient pool analysis across the United States, EU5 countries, and Japan from 2020 to 2034.
• Ductal Carcinoma in Situ clinical trials are advancing innovative therapies aimed at improving early breast cancer management, enhancing patient outcomes, and exploring novel treatment strategies for this non-invasive cancer stage.

Ductal Carcinoma in Situ Overview

Ductal Carcinoma in Situ (DCIS) is a non-invasive form of breast cancer where abnormal cells are found in the lining of breast ducts but have not spread beyond the duct wall into surrounding breast tissue. It is considered the earliest form of breast cancer and is often detected through routine mammography screening. While DCIS is non-invasive, if left untreated, it may progress to invasive breast cancer in some cases, making appropriate management crucial for patient outcomes.

Get a Free sample for the Ductal Carcinoma in Situ Market Report:
https://www.delveinsight.com/sample-request/ductal-carcinoma-in-situ-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Ductal Carcinoma in Situ Market

The dynamics of the Ductal Carcinoma in Situ market are anticipated to change in the coming years owing to the rising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period 2020-2034. The market is witnessing growth driven by emerging targeted therapies, increasing awareness, and advancements in early breast cancer detection, improving patient outcomes and expanding treatment options globally.

Ductal Carcinoma in Situ Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Ductal Carcinoma in Situ epidemiology trends @ Ductal Carcinoma in Situ Epidemiological Insights

Ductal Carcinoma in Situ Epidemiology Segmentation:

The Ductal Carcinoma in Situ market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Prevalent Cases of Ductal Carcinoma in Situ
• Diagnosed Prevalent Cases of Ductal Carcinoma in Situ
• Age-specific Cases of Ductal Carcinoma in Situ
• Gender-specific Cases of Ductal Carcinoma in Situ
• Stage-specific Cases of Ductal Carcinoma in Situ
• Country-wise Breakdown of Ductal Carcinoma in Situ

Ductal Carcinoma in Situ Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ductal Carcinoma in Situ market or expected to get launched during the study period. The analysis covers Ductal Carcinoma in Situ market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ductal Carcinoma in Situ Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ductal Carcinoma in Situ Therapies and Key Companies

• Emerging Pipeline Therapies: Atossa Therapeutics Inc
• Novel Targeted Approaches: F. Hoffmann-La Roche Ltd
• Immunotherapy Candidates: ImmunoRestoration Inc
• Innovative Treatment Platforms: SELLAS Life Sciences Group Inc, University of Pittsburgh, Marker Therapeutics Inc

To know more about Ductal Carcinoma in Situ treatment, visit @ Ductal Carcinoma in Situ Medications

Ductal Carcinoma in Situ Market Drivers

• Rising awareness of early-stage breast cancer and the importance of screening programs
• Advancements in precision diagnostics and molecular testing, including breakthrough devices like DCISionRT®
• Increasing healthcare expenditure and improved access to oncology care globally
• Growing patient population due to enhanced detection through routine mammography screening
• Development of novel targeted therapies focused on personalized treatment approaches
• Better understanding of disease pathogenesis contributing to innovative therapeutic development
• Expansion of treatment options beyond traditional surgical and radiation approaches
• Increasing focus on improving quality of life and reducing overtreatment in early-stage disease

Ductal Carcinoma in Situ Market Barriers

• Challenges in differentiating patients who need aggressive treatment from those who can be managed conservatively
• Concerns about overtreatment and unnecessary interventions for low-risk DCIS cases
• High cost of advanced diagnostic tests and limited reimbursement in certain regions
• Stringent regulatory requirements and lengthy approval timelines for novel therapies
• Limited long-term efficacy data for emerging targeted treatments
• Variability in treatment guidelines across different geographic regions
• Patient anxiety and decision-making challenges regarding treatment options
• Lack of standardized risk stratification tools in clinical practice

Scope of the Ductal Carcinoma in Situ Market Report

• Coverage: 7MM 
• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Key Ductal Carcinoma in Situ Companies: Atossa Therapeutics Inc, F. Hoffmann-La Roche Ltd, ImmunoRestoration Inc, SELLAS Life Sciences Group Inc, University of Pittsburgh, Marker Therapeutics Inc, and others
• Key Ductal Carcinoma in Situ Therapies: Multiple emerging therapies in Phase II and Phase III development stages
• Ductal Carcinoma in Situ Therapeutic Assessment: Current marketed and emerging therapies
• Ductal Carcinoma in Situ Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Ductal Carcinoma in Situ Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

The Febrile Neutropenia market is expected to experience continued expansion during the forecast period, driven by rising cancer incidence and chemotherapy treatment volumes, increasing awareness of neutropenia risks, and the development of outpatient cancer care. The entry and expansion of low-cost biosimilars alongside new emerging therapies is anticipated to significantly transform the Febrile Neutropenia market landscape and treatment dynamics.

DelveInsight’s “Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Febrile Neutropenia, historical and forecasted epidemiology as well as the Febrile Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan.

The Febrile Neutropenia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Febrile Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Febrile Neutropenia Market Forecast

Some of the key facts of the Febrile Neutropenia Market Report:

• The Febrile Neutropenia market size was valued at USD 4,750 Million in 2025 and is anticipated to reach USD 6,700 Million by 2036, growing at a CAGR of 3.2% during the study period (2026-2036).
• In June 2025, Evive Biotech signed an exclusive distribution agreement with Lenis farmacevtika to commercialize efbemalenograstim alfa across eight markets, including Slovenia, Croatia, Serbia, and others in the Adriatic region. The partnership aims to expand regional access to innovative oncology supportive care, leveraging Lenis’ strong distribution network across Central and Eastern Europe.
• In April 2025, Evive Biotech and I’rom Group announced the start of collaboration to develop efbemalenograstim in Japan. The partnership will focus on advancing a same-day dosing regimen with chemotherapy supported by global clinical data and investigator-led studies showing comparable safety and efficacy to next-day dosing.
• In November 2022, Evive Biotech announced that it has entered into a license agreement with Acrotech Biopharma, a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc., to commercialize RYZNEUTA in the US.
• The total chemotherapy usage per year in the 7MM was 1,906,000 in 2025, of which the United States accounted for the largest share at approximately 36%.
• In 2025, chemotherapy-associated cases accounted for 692,000 in the US and this number is projected to increase to 841,500 by 2036, growing at a CAGR of 1.8%.
• Among the EU4 and the UK, Germany recorded the highest number of incident cases in 2025, accounting for approximately 24% of the total incident cases across these regions.
• Key Febrile Neutropenia Companies: Evive Biotech, Acrotech Biopharma, APOGEPHA Arzneimittel GmbH, Teva Pharmaceutical, Assertio Holdings (Spectrum Pharmaceuticals), Kyowa Kirin, Terumo Corporation, BeyondSpring Pharmaceuticals, and others
• Key Febrile Neutropenia Therapies: RYZNEUTA [F-627 (efbemalenograstim alfa)], Lipegfilgrastim (LONQUEX), Filgrastim (GRANIX), Eflapegrastim-xnst (ROLVEDON), Pegfilgrastim (G-LASTA), Plinabulin, and others
• The febrile neutropenia epidemiology based on gender analyzed that the incidence shows a higher trend among males compared to females, suggesting a relatively greater susceptibility in male patients.
• Febrile neutropenia shows a higher incidence rate in hematological malignancies than in solid tumors; however, the overall number of cases is greater in solid tumors due to their higher patient population.

Febrile Neutropenia Overview

Febrile Neutropenia is a high-risk clinical condition characterized by the development of fever during a period of significant neutropenia, typically following cytotoxic chemotherapy. It represents a profound disruption of innate immunity, making even minor infections potentially life-threatening. The condition is managed as a medical emergency with immediate empiric broad-spectrum antibiotics, and supportive measures such as Granulocyte-Colony Stimulating Factor (G-CSF) agents may be used in selected cases based on patient risk status.

Get a Free sample for the Febrile Neutropenia Market Report:
https://www.delveinsight.com/sample-request/febrile-neutropenia-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Febrile Neutropenia Market

The dynamics of the Febrile Neutropenia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and increasing biosimilar penetration during the forecast period 2022-2036. The market has transitioned from a high-cost, monopolistic landscape dominated by originator biologics to a more competitive, volume-driven market with biosimilars now playing a central role in driving growth and access.

Febrile Neutropenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Febrile Neutropenia epidemiology trends @ Febrile Neutropenia Epidemiological Insights

Febrile Neutropenia Epidemiology Segmentation:

The Febrile Neutropenia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

• Patient Burden Assessment
• Chemotherapy Usage
• At Risk Patient Pool for Febrile Neutropenia
• Total Incident Cases of Febrile Neutropenia
• Febrile Neutropenia Incident Cases by Cancer Types (Solid vs. Hematologic Malignancies)
• Gender-specific Incident Cases of Febrile Neutropenia
• Comorbidity-Specific Rate of Febrile Neutropenia
• Prophylaxis/Treatment Eligible Patient Pool

Febrile Neutropenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Febrile Neutropenia market or expected to get launched during the study period. The analysis covers Febrile Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Febrile Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Febrile Neutropenia Therapies and Key Companies

• RYZNEUTA [F-627 (efbemalenograstim alfa)]: Evive Biotech/Acrotech Biopharma/APOGEPHA Arzneimittel GmbH
• Lipegfilgrastim (LONQUEX): Teva Pharmaceutical
• Filgrastim (GRANIX): Teva Pharmaceutical
• Eflapegrastim-xnst (ROLVEDON): Assertio Holdings (Spectrum Pharmaceuticals)
• Pegfilgrastim (G-LASTA): Kyowa Kirin/Terumo Corporation
• Plinabulin: BeyondSpring Pharmaceuticals

To know more about Febrile Neutropenia treatment, visit @ Febrile Neutropenia Medications

Febrile Neutropenia Market Drivers

• Rising cancer incidence across global markets, primarily driven by aging populations, improved screening programs, and enhanced diagnostic capabilities
• Increasing reliance on chemotherapy as a standard treatment approach, elevating the risk of treatment-related complications
• Growing demand for novel therapies in community oncology clinics with competitive clinical profiles
• Expanding demand for treatments that are easy to administer, reduce hospital visits, and improve patient outcomes
• Entry and expansion of low-cost biosimilars improving accessibility and treatment adoption
• Transition toward outpatient cancer care models requiring effective supportive therapies
• Improved access to oncology care in emerging markets

Febrile Neutropenia Market Barriers

• Rising antimicrobial resistance complicating empirical therapy choices and treatment outcomes
• Stringent regulatory requirements and lengthy approval timelines for novel therapies
• Delayed market entry of key supportive care therapies in certain regions like Japan
• Limited late-stage pipeline assets constraining innovation and near-term growth
• Increasing biosimilar penetration driving price pressure and long-term revenue decline for innovator products
• Structural shrinking of short-acting G-CSF market opportunity
• Reimbursement-driven delays in febrile neutropenia access in certain markets
• Gaps in diagnosis and risk stratification capabilities
• Lack of comprehensive epidemiological data in certain geographies

Scope of the Febrile Neutropenia Market Report

• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan]
• Key Febrile Neutropenia Companies: Evive Biotech, Acrotech Biopharma, APOGEPHA Arzneimittel GmbH, Teva Pharmaceutical, Assertio Holdings (Spectrum Pharmaceuticals), Kyowa Kirin, Terumo Corporation, BeyondSpring Pharmaceuticals, and others
• Key Febrile Neutropenia Therapies: RYZNEUTA [F-627 (efbemalenograstim alfa)], Lipegfilgrastim (LONQUEX), Filgrastim (GRANIX), Eflapegrastim-xnst (ROLVEDON), Pegfilgrastim (G-LASTA), Plinabulin, and others
• Febrile Neutropenia Therapeutic Assessment: Febrile Neutropenia current marketed and emerging therapies
• Febrile Neutropenia Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Porter’s five forces, Market entry strategies
• Febrile Neutropenia Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market is anticipated to experience substantial growth during the forecast period, driven by rising cancer incidence, increasing chemotherapy use, and the introduction of multiple late-stage pipeline therapies. Additionally, the absence of FDA-approved preventive therapies and limited treatment options create a significant unmet need, with the emergence of novel therapeutic candidates targeting diverse mechanisms expected to significantly transform the CIPN market landscape and treatment dynamics.

DelveInsight’s “Chemotherapy-Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of CIPN, historical and forecasted epidemiology as well as the CIPN market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The CIPN market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

To Know in detail about the CIPN market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; CIPN Market Forecast

Some of the key facts of the Chemotherapy-Induced Peripheral Neuropathy Market Report:

• The CIPN market size was valued at approximately USD 1,000 Million in 2025 and is anticipated to grow with a significant CAGR of 14.2% during the study period (2026-2036), reaching approximately USD 3,800 Million by 2036.
• In February 2026, Dogwood Therapeutics announced that it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase IIb chemotherapy-induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top-line results to be available during the third quarter of 2026.
• In December 2025, Dogwood Therapeutics reported positive interim results from 97 patients in the ongoing Phase IIb Halneuron study in chemotherapy-induced neuropathic pain. An independent statistical review of unblinded data indicated that patients receiving Halneuron showed a clear improvement in pain compared to placebo over the four-week treatment period.
• In June 2025, the European Patent Office granted a European Union patent (licensed from Yale University) for OSM-0205, and Osmol is securing financing to begin a Phase I trial, with Phase II studies in CIPN planned for the second half of 2026.
• The total 7MM incident cases of CIPN in 2025 were approximately 1.6 million cases.
• Among the 7MM countries, the highest market size for CIPN was observed in the United States.
• In 2025, the total number of incident cases of CIPN in the United States was approximately 647,650 cases, with severe CIPN accounting for approximately 239,600 cases, followed by mild (approximately 208,550 cases) and moderate (approximately 199,500 cases).
• Key CIPN Companies: Averitas Pharma (Grünenthal), Dogwood Therapeutics, AlgoTherapeutix, Sanodyne Therapeutics/Toray Industries, Sonnet BioTherapeutics, Asahi Kasei Pharma, WinSanTor, VM Therapeutics, Tarian Pharma, Bausch Health, Osmol, and others.
• Key CIPN Therapies: Capsaicin 8% (QUTENZA), Halneuron (tetrodotoxin), ATX01 (amitriptyline hydrochloride 15%), SNT-001/TRK-7501, SON-080, Recomodulin (ART-123), Pirenzepine (WST-057), VMD-3866, TAR-0520 (Tarian Gel), Larsuscosterol (DUR-928), OSM-0205, and others.
• The CIPN epidemiology based on cancer type analyzed that in 2025, breast and colorectal cancers accounted for the majority share of CIPN incidence across the EU4 and the UK, with breast cancer associated with approximately 123,450 CIPN cases and colorectal cancer contributing approximately 118,600 cases.

Chemotherapy-Induced Peripheral Neuropathy Overview

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common complication of neurotoxic chemotherapy, affecting up to 90% of patients treated with agents such as platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors. Although not life-threatening, its chronic nature significantly impairs quality of life and contributes to long-term survivorship burden. CIPN is characterized by distal axonal degeneration and functional neuronal alterations, leading to persistent sensory symptoms such as tingling, numbness, burning pain, and a “glove and stocking” distribution that may last for months or years.

Get a Free sample for the CIPN Market Report: https://www.delveinsight.com/sample-request/cipn-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Chemotherapy-Induced Peripheral Neuropathy Market

The dynamics of the CIPN market are anticipated to change significantly in the coming years owing to the expected launch of emerging therapies during the forecast period 2026-2036. Currently, there are no FDA-approved therapies for CIPN prevention and only limited treatment options, with duloxetine being the only agent supported by moderate evidence. Management remains largely symptomatic and severity-based, relying on off-label therapies.

Chemotherapy-Induced Peripheral Neuropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving CIPN epidemiology trends @ CIPN Epidemiological Insights

Chemotherapy-Induced Peripheral Neuropathy Epidemiology Segmentation:

The CIPN market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

• Total Incident Population of CIPN
• Severity-specific Incident Population of CIPN
• Incident Population of CIPN by Cancer Type
• Total Treated Population of CIPN

Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the CIPN market or expected to get launched during the study period. The analysis covers CIPN market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the CIPN Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chemotherapy-Induced Peripheral Neuropathy Therapies and Key Companies

Treatment Therapies:

• Capsaicin 8% (QUTENZA): Averitas Pharma (Grünenthal)
• Halneuron (tetrodotoxin): Dogwood Therapeutics
• ATX01 (amitriptyline hydrochloride 15%): AlgoTherapeutix
• SNT-001/TRK-7501: Sanodyne Therapeutics/Toray Industries
• SON-080: Sonnet BioTherapeutics
• VMD-3866: VM Therapeutics
• Larsuscosterol (DUR-928): Bausch Health

Prevention Therapies:

• Recomodulin (ART-123): Asahi Kasei Pharma
• Pirenzepine (WST-057): WinSanTor
• TAR-0520 (Tarian Gel): Tarian Pharma

To know more about CIPN treatment, visit @ CIPN Medications

Chemotherapy-Induced Peripheral Neuropathy Market Drivers

• Rising cancer incidence and increased chemotherapy use globally, significantly expanding CIPN prevalence
• Expanding use of neurotoxic chemotherapeutic agents such as platinum compounds, taxanes, and proteasome inhibitors
• No approved preventive therapy and limited treatment options, creating substantial unmet need
• Duloxetine as the only guideline-recommended first-line therapy, with real-world use frequently delayed due to step-therapy requirements
• Growing demand for novel therapies in community oncology clinics with competitive clinical profiles
• Increasing focus on mechanism-based approaches targeting neuroinflammation, oxidative stress, and neuronal damage
• Rising awareness of CIPN’s impact on quality of life and treatment continuity
• Strong pipeline of emerging therapies targeting diverse mechanisms including TRPV1 modulation, sodium channel inhibition, and neuroprotection

Chemotherapy-Induced Peripheral Neuropathy Market Barriers

• Lack of standardized diagnostic criteria complicating disease evaluation and clinical trial design
• Complex and multifactorial pathobiology hindering identification of consistent therapeutic targets
• Limited effectiveness of current off-label therapies with modest and inconsistent efficacy
• Safety concerns with existing pharmacological options, particularly systemic adverse effects
• Insufficient evidence and no clinical guidelines for CIPN prevention
• Biological complexity as a barrier to targeted therapeutics development
• Challenges in reversal of “coasting” and long-term chronic neuropathy
• High cost of emerging novel therapies and potential reimbursement challenges
• Variability in patient response limiting treatment standardization

Scope of the Chemotherapy-Induced Peripheral Neuropathy Market Report

• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key CIPN Companies: Averitas Pharma (Grünenthal), Dogwood Therapeutics, AlgoTherapeutix, Sanodyne Therapeutics/Toray Industries, Sonnet BioTherapeutics, Asahi Kasei Pharma, WinSanTor, VM Therapeutics, Tarian Pharma, Bausch Health, Osmol, and others
• Key CIPN Therapies: Capsaicin 8% (QUTENZA), Halneuron (tetrodotoxin), ATX01 (amitriptyline hydrochloride 15%), SNT-001/TRK-7501, SON-080, Recomodulin (ART-123), Pirenzepine (WST-057), VMD-3866, TAR-0520, Larsuscosterol (DUR-928), and others
• CIPN Therapeutic Assessment: Emerging therapies and current treatment landscape
• CIPN Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, Porter’s five forces, market entry strategies
• CIPN Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

The Agitation in Alzheimer’s Disease market is anticipated to experience substantial growth during the forecast period, driven by rising prevalence of Alzheimer’s disease, increasing recognition of behavioral symptoms, and the introduction of multiple late-stage pipeline therapies. Additionally, the approval of first-in-class targeted treatments and the emergence of novel therapeutic candidates with differentiated mechanisms of action are expected to significantly transform the Agitation in Alzheimer’s Disease market landscape and treatment dynamics.

DelveInsight’s “Agitation in Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Agitation in Alzheimer’s Disease, historical and forecasted epidemiology as well as the Agitation in Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Agitation in Alzheimer’s Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

To Know in detail about the Agitation in Alzheimer’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Agitation in Alzheimer’s Disease Market Forecast

Some of the key facts of the Agitation in Alzheimer’s Disease Market Report:

• The Agitation in Alzheimer’s Disease market size surpassed USD 600 Million in 2025 and is anticipated to grow with a significant CAGR of 14.9% during the study period (2026-2036), reaching approximately USD 2,800 Million by 2036.
• In September 2024, Otsuka Pharmaceutical reported that brexpiprazole (REXULTI) received regulatory approval in Japan for an additional indication: treating “an excessive motor activity or physically/verbally aggressive behavior” linked to mood changes and irritability in Alzheimer’s disease patients. This indication aligns with the US and other countries’ approval for agitation symptoms associated with dementia due to Alzheimer’s disease.
• In November 2025, Suven Life Sciences reported that its global Phase III clinical trial of masupirdine (SUVN-502) achieved 50% patient enrollment for agitation in Alzheimer’s disease, with the multicenter, randomized, double-blind, placebo-controlled study ongoing across North America and Europe.
• In April 2025, Axsome Therapeutics presented positive pivotal Phase III results from the ACCORD-2 trial evaluating AXS-05 (AUVELITY) for the treatment of agitation associated with Alzheimer’s disease at the 2025 American Academy of Neurology (AAN) Annual Meeting.
• In February 2026, the US FDA accepted Axsome Therapeutics’ sNDA for AUVELITY for the treatment of agitation associated with Alzheimer’s disease and granted the application Priority Review designation, with a PDUFA target action date set for April 30, 2026.
• In November 2024, Exciva GmbH reported that its lead candidate EXV-802 received Fast Track Designation from the US FDA for the treatment of agitation associated with Alzheimer’s disease.
• The total 7MM diagnosed prevalent cases of Agitation in Alzheimer’s Disease in 2025 were approximately 11 million cases.
• Among the 7MM countries, the highest number of Agitation in Alzheimer’s Disease cases were observed in the United States, accounting for approximately 49% of the total.
• In 2025, there were approximately 5 million diagnosed cases of Agitation in Alzheimer’s Disease in the United States.
• Key Agitation in Alzheimer’s Disease Companies: Bristol-Myers Squibb, Suven Life Sciences, Axsome Therapeutics, Exciva GmbH, IGC Pharma, Johnson and Johnson, Teikoku Pharma, Ono Pharma, Neumora Therapeutics, Otsuka Pharmaceutical, Lundbeck, Karuna Therapeutics, and others.
• Key Agitation in Alzheimer’s Disease Therapies: Brexpiprazole (REXULTI), Masupirdine (SUVN-502), AUVELITY (AXS-05), COBENFY (xanomeline/trospium chloride), EXV-801 ± dextromethorphan, Melatonin/tetrahydrocannabinol (IGC-AD1), and others.
• The Agitation in Alzheimer’s Disease epidemiology based on gender analyzed that diagnosed prevalent cases are predominantly female, with females accounting for approximately 70% and males accounting for approximately 30% across EU4 and the UK in 2025.

Agitation in Alzheimer’s Disease Overview

Agitation in Alzheimer’s Disease is a common neuropsychiatric manifestation characterized by emotional distress, excessive motor activity, irritability, and, at times, aggressive behaviors, arising from progressive neurodegeneration affecting cognitive and behavioral regulation. The presentation varies across disease stages but often includes restlessness, verbal or physical aggression, mood lability, and resistance to care, significantly impacting patient quality of life and caregiver burden.

Get a Free sample for the Agitation in Alzheimer’s Disease Market Report:  https://www.delveinsight.com/sample-request/agitation-in-alzheimer-disease?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Agitation in Alzheimer’s Disease Market

The dynamics of the Agitation in Alzheimer’s Disease market are anticipated to change significantly in the coming years owing to the expected launch of emerging therapies during the forecast period 2026-2036. Brexpiprazole (REXULTI) became the first pharmacological treatment approved in the US specifically for agitation associated with Alzheimer’s dementia in 2023, addressing a significant unmet need in behavioral symptom management.

Agitation in Alzheimer’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Agitation in Alzheimer’s Disease epidemiology trends @ Agitation in Alzheimer’s Disease Epidemiological Insights

Agitation in Alzheimer’s Disease Epidemiology Segmentation:

The Agitation in Alzheimer’s Disease market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Alzheimer’s Disease
• Total Diagnosed Prevalent Cases of Agitation in Alzheimer’s Disease
• Gender-specific Diagnosed Prevalent Cases of Agitation in Alzheimer’s Disease
• Age-specific Diagnosed Prevalent Cases of Agitation in Alzheimer’s Disease
• Total Treated Cases of Agitation in Alzheimer’s Disease

Agitation in Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Agitation in Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Agitation in Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Agitation in Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Agitation in Alzheimer’s Disease Therapies and Key Companies

• Brexpiprazole (REXULTI): Otsuka Pharmaceutical/Lundbeck
• Masupirdine (SUVN-502): Suven Life Sciences
• AUVELITY (AXS-05): Axsome Therapeutics
• COBENFY (xanomeline/trospium chloride): Bristol Myers Squibb/Karuna Therapeutics
• EXV-801 ± Dextromethorphan: Exciva GmbH
• Melatonin/tetrahydrocannabinol (IGC-AD1): IGC Pharma

To know more about Agitation in Alzheimer’s Disease treatment, visit @ Agitation in Alzheimer’s Disease Medications

Agitation in Alzheimer’s Disease Market Drivers

• Rising prevalence of Alzheimer’s disease worldwide, directly expanding the patient pool for agitation-related treatment
• High occurrence of agitation among Alzheimer’s patients, affecting a significant proportion and creating strong unmet need
• Growing awareness and improved diagnosis through standardized behavioral assessment tools and caregiver-reported observations
• Approval of novel targeted therapies specifically indicated for agitation in Alzheimer’s disease, including REXULTI and anticipated approval of AUVELITY
• Strong pipeline of emerging drugs with differentiated mechanisms, including masupirdine, AXS-05, COBENFY, and investigational candidates
• Increasing research and development investments in CNS and neuropsychiatric drug development
• Growing caregiver burden and clinical need, with agitation substantially increasing caregiver stress, hospitalization risk, and institutional care needs
• Shift toward non-antipsychotic treatment options with improved safety profiles, reducing dependence on off-label therapies

Agitation in Alzheimer’s Disease Market Barriers

• Limited efficacy and safety concerns with existing off-label pharmacological options, particularly antipsychotics
• Lack of standardized assessment tools for consistent diagnosis and monitoring
• Pharmacological management constrained by narrow therapeutic margin, where modest efficacy is frequently offset by safety risks
• Structural and system-level barriers undermining scalable implementation of non-pharmacological strategies
• Methodological heterogeneity limiting reproducibility and interpretability of clinical evidence
• High cost of emerging novel therapies and potential reimbursement challenges
• Variability in treatment patterns and patient outcomes across regions due to heterogeneous care practices
• Continued reliance on off-label antipsychotic therapies reflecting structural gaps in the treatment landscape

Scope of the Agitation in Alzheimer’s Disease Market Report

• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Agitation in Alzheimer’s Disease Companies: Bristol-Myers Squibb, Suven Life Sciences, Axsome Therapeutics, Exciva GmbH, IGC Pharma, Johnson and Johnson, Teikoku Pharma, Ono Pharma, Neumora Therapeutics, Otsuka Pharmaceutical, Lundbeck, Karuna Therapeutics, and others
• Key Agitation in Alzheimer’s Disease Therapies: Brexpiprazole (REXULTI), Masupirdine (SUVN-502), AUVELITY (AXS-05), COBENFY (xanomeline/trospium chloride), EXV-801 ± dextromethorphan, Melatonin/tetrahydrocannabinol (IGC-AD1), and others
• Agitation in Alzheimer’s Disease Therapeutic Assessment: Current marketed and emerging therapies
• Agitation in Alzheimer’s Disease Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, Porter’s five forces, market entry strategies
• Agitation in Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

 

The Multiple Myeloma market is anticipated to experience steady growth during the forecast period, driven by rising disease incidence among aging populations, therapeutic advancements, and the introduction of multiple innovative late-stage pipeline therapies. Additionally, the emergence of novel treatment modalities including CAR-T cell therapies, bispecific antibodies, and next-generation immunomodulatory agents is expected to significantly transform the Multiple Myeloma market landscape and treatment dynamics.

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Multiple Myeloma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast

Some of the key facts of the Multiple Myeloma Market Report:

• The Multiple Myeloma market size was valued at USD 28,722 Million in 2025 and is anticipated to grow with a CAGR of 3.3% during the study period (2026-2036), reaching approximately USD 43,578 Million by 2036.
• In February 2026, AstraZeneca announced that the Phase II (DURGA-3) trial data is projected to be read out in H1 2026, followed by results from the Phase I (DURGA-2) study in H2 2026 and the Phase I/II (DURGA-1) trial in 2027 for AZD0120, a BCMA x CD19 targeted therapy.
• In February 2026, the US FDA accepted the BLA for anito-cel (CART-ddBCMA) for the treatment of adult patients with relapsed or refractory multiple myeloma in the fourth-line setting, with a PDUFA target action date of December 23, 2026. The submission is supported by data from the Phase I study and the pivotal Phase II iMMagine-1 trial.
• In January 2026, Regeneron Corporate Presentation highlighted four registrational trials underway for LYNOZYFIC (linvoseltamab), with four more trials expected to be initiated in 2026, including LINKER-MM5, LINKER-MM7, LINKER-MM8, and LINKER-SMM2, with pivotal data anticipated starting in 2027.
• In January 2026, according to Sanofi’s presentation, SARCLISA (isatuximab) is being evaluated in a subcutaneous formulation for relapsed or refractory multiple myeloma, with anticipated approval in the United States, Europe, and Japan in H1 2026.
• The total 7MM incident cases of Multiple Myeloma in 2025 were approximately 60,000 cases.
• Among the 7MM countries, the highest number of Multiple Myeloma cases were observed in the United States.
• In 2025, there were 34,097 incident cases of Multiple Myeloma in the United States, which are expected to continue increasing through 2036.
• Key Multiple Myeloma Companies: Bristol-Myers Squibb (Celgene), Takeda Pharmaceutical, Janssen Pharmaceutical, AbbVie, Karyopharm Therapeutics, AstraZeneca (Gracell Biotechnologies), Arcellx/Gilead (Kite), Cartesian Therapeutics, RAPA Therapeutics, C4 Therapeutics, Regeneron Pharmaceuticals, Sanofi, and others.
• Key Multiple Myeloma Therapies: REVLIMID, POMALYST, VELCADE, KYPROLIS, NINLARO, EVOMELA, DARZALEX, LYNOZYFIC, SARCLISA, AZD0120, VENCLEXTA, Anito-cel (CART-ddBCMA), Etentamig (ABBV-383), Iberdomide (CC-220), BMS-986393 (CC-95266), Mezigdomide (CC-92480), and others.
• The Multiple Myeloma epidemiology based on age analyzed that in the United States, the 65+ age group accounted for approximately 73% of multiple myeloma cases in 2025, while patients 55–64 years represented approximately 17%, and those under 54 years accounted for only approximately 10%.

Multiple Myeloma Overview

Multiple Myeloma is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from accumulating terminally differentiated monoclonal plasma cells in the bone marrow. Multiple Myeloma is characterized by uncontrolled proliferation of clonal plasma cells, causing various complications leading to organ dysfunction. It accounts for 10% of hematological malignancies and grows from a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS), found in 3% of those over 50 and progressing to myeloma at a rate of 1% per year.

Get a Free sample for the Multiple Myeloma Market Report: https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Multiple Myeloma Market

The dynamics of the Multiple Myeloma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and continued expansion of treatment options during the forecast period 2026-2036. The treatment landscape has expanded significantly with multiple drug classes targeting distinct disease pathways, including immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies, CAR-T cell therapies, and bispecific antibodies.

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiological Insights

Multiple Myeloma Epidemiology Segmentation:

The Multiple Myeloma market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

• Total Incident Cases of Multiple Myeloma
• Total Symptomatic Incident Cases of Multiple Myeloma
• Gender-specific Incident Cases of Multiple Myeloma
• Age-specific Incident Cases of Multiple Myeloma
• Transplant Eligible and Ineligible Cases in Multiple Myeloma
• Total Treated Cases Across the Lines of Therapies

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Multiple Myeloma Therapies and Key Companies

• REVLIMID (Lenalidomide): Bristol-Myers Squibb (Celgene)
• POMALYST (Pomalidomide): Bristol-Myers Squibb (Celgene)
• VELCADE (Bortezomib): Takeda Pharmaceutical and Janssen Pharmaceutical
• KYPROLIS (Carfilzomib): Amgen
• NINLARO (Ixazomib): Takeda Pharmaceutical
• DARZALEX (Daratumumab): Janssen Pharmaceutical
• SARCLISA (Isatuximab): Sanofi
• LYNOZYFIC (Linvoseltamab): Regeneron Pharmaceuticals
• AZD0120: AstraZeneca (Gracell Biotechnologies)
• Anito-cel (CART-ddBCMA): Arcellx/Gilead (Kite)
• Etentamig (ABBV-383): AbbVie
• VENCLEXTA (Venetoclax): AbbVie and Roche (Genentech)
• Iberdomide (CC-220): Bristol-Myers Squibb
• BMS-986393 (CC-95266): Bristol-Myers Squibb

To know more about Multiple Myeloma treatment, visit @ Multiple Myeloma Medications

Multiple Myeloma Market Drivers

• Rising disease incidence and aging global population, particularly among elderly patients
• Advancements in treatment modalities including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T cell therapies, and bispecific antibodies
• Improved diagnostic capabilities and increasing awareness initiatives enabling earlier detection
• Expansion of novel immunotherapies and next-generation cellular therapies
• Growing adoption of quadruplet regimens incorporating anti-CD38 monoclonal antibodies
• Increasing understanding of high-risk cytogenetic abnormalities enabling personalized treatment strategies
• Emergence of MRD (minimal residual disease) assessment as a critical biomarker for treatment optimization
• Strong pipeline of emerging therapies including trispecific antibodies and novel CELMoDs

Multiple Myeloma Market Barriers

• Disease relapse remains common due to clonal heterogeneity and evolving resistance mechanisms
• Treatment resistance and limited durability of response in some patients
• Lack of curative therapies despite therapeutic advances
• High early mortality rates in certain patient populations
• Challenges in optimal treatment sequencing and combination strategies
• High cost of advanced therapies including CAR-T cell therapies and bispecific antibodies
• Limited reimbursement in several regions for novel expensive treatments
• Variability in patient response and the need for personalized treatment approaches
• Assessment challenges due to lack of standardized definition of lines of therapy (LoT)

Scope of the Multiple Myeloma Market Report

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Study Period: 2022-2036
• Key Multiple Myeloma Companies: Bristol-Myers Squibb (Celgene), Takeda Pharmaceutical, Janssen Pharmaceutical, AbbVie, Karyopharm Therapeutics, AstraZeneca (Gracell Biotechnologies), Arcellx/Gilead (Kite), Cartesian Therapeutics, RAPA Therapeutics, C4 Therapeutics, Regeneron Pharmaceuticals, Sanofi, and others
• Key Multiple Myeloma Therapies: REVLIMID, POMALYST, VELCADE, KYPROLIS, NINLARO, DARZALEX, SARCLISA, LYNOZYFIC, AZD0120, VENCLEXTA, Anito-cel, Etentamig, Iberdomide, BMS-986393, Mezigdomide, and others
• Multiple Myeloma Therapeutic Assessment: Current marketed and emerging therapies
• Multiple Myeloma Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, Porter’s five forces, market entry strategies
• Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com

The Neuroendocrine Carcinoma market is projected to experience robust growth during the forecast period, driven by increasing incidence of neuroendocrine malignancies, advancements in diagnostic technologies, and the emergence of promising late-stage pipeline therapies. The introduction of multiple innovative therapeutic candidates is expected to significantly transform the Neuroendocrine Carcinoma market landscape and treatment dynamics.

DelveInsight’s “Neuroendocrine Carcinoma Market Insights, Epidemiology, and Market Forecast-2036” report offers an in-depth understanding of Neuroendocrine Carcinoma, historical and forecasted epidemiology as well as the Neuroendocrine Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Neuroendocrine Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

To Know in detail about the Neuroendocrine Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroendocrine Carcinoma Market Forecast

Some of the key facts of the Neuroendocrine Carcinoma Market Report:

• The Neuroendocrine Carcinoma market size was valued at approximately USD 30 Million in 2025 and is anticipated to grow with a significant CAGR of 15.2% during the study period (2026-2036), reaching approximately USD 120 Million by 2036.
• In February 2026, Merck presented data at the 2026 American Society of Clinical Oncology (ASCO) GU Symposium, including Phase II efficacy and safety results of the DLL3 T-cell engager gocatamig (MK-6070) in neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms, highlighting its oncology pipeline advancement.
• In October 2025, Zai Lab reported that its Neuroendocrine Carcinoma programs are advancing toward the registrational Phase in 2026, reflecting continued clinical progress in DLL3-targeted therapies for high-grade neuroendocrine malignancies.
• In July 2025, Phase I dose-escalation results for obrixtamig (BI 764532), a DLL3/CD3 IgG-like T-cell engager, were reported in patients with DLL3-positive SCLC and Neuroendocrine Carcinoma.
• The total 7MM incident cases of Neuroendocrine Carcinoma in 2025 were approximately 20,000 cases.
• Among the 7MM countries, the highest number of Neuroendocrine Carcinoma cases were observed in the United States.
• In 2025, there were approximately 30,000 total neuroendocrine neoplasm incident cases in the United States, including around 9,000 cases of Neuroendocrine Carcinoma, with nearly 950 cases attributed to extrapulmonary Neuroendocrine Carcinoma.
• Key Neuroendocrine Carcinoma Companies: Boehringer Ingelheim, Oxford BioTherapeutics, Amgen, Zai Lab, MediLink Therapeutics, Merck, Daiichi Sankyo, Vyriad, Phanes Therapeutics, and others.
• Key Neuroendocrine Carcinoma Therapies: Obrixtamig (BI 764532), Tarlatamab-dlle (IMDELLTRA), Zocilurtatug pelitecan (ZL-1310), Gocatamig (MK-6070), Voyager-V1 in combination with pembrolizumab, Peluntamig (PT217), IDE849, MT-4561, Clesitamig (RO7616789), and others.
• The Neuroendocrine Carcinoma epidemiology analysis indicates that in 2025, Japan reported nearly 7,000 total Neuroendocrine Carcinoma incident cases and approximately 4,000 incident cases of Neuroendocrine Carcinoma, reflecting a measurable burden of these heterogeneous tumors.

Neuroendocrine Carcinoma Overview

Neuroendocrine Carcinoma is a rare and highly aggressive malignancy that arises from neuroendocrine cells, which are specialized cells possessing characteristics of both nerve cells and hormone-producing endocrine cells. These cells are widely distributed throughout the body, particularly in organs such as the lungs, gastrointestinal tract, pancreas, and other endocrine tissues. This report focuses exclusively on extrapulmonary Neuroendocrine Carcinoma, excluding pulmonary forms, to provide a more precise and targeted analysis of disease characteristics, trends, and clinical treatment insights.

Get a Free sample for the Neuroendocrine Carcinoma Market Report:  https://www.delveinsight.com/sample-request/neuroendocrine-carcinoma-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Neuroendocrine Carcinoma Market

The dynamics of the Neuroendocrine Carcinoma market are anticipated to change significantly in the coming years owing to the expected launch of emerging therapies during the forecast period 2026-2036. Currently, there are no specifically approved Neuroendocrine Carcinoma marketed drugs. Treatment strategies largely rely on conventional approaches such as platinum-based chemotherapy regimens, including cisplatin or carboplatin combined with etoposide, along with somatostatin analogs, mTOR pathway inhibitors such as everolimus, and immunotherapy-based approaches.

Neuroendocrine Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Neuroendocrine Carcinoma epidemiology trends @ Neuroendocrine Carcinoma Epidemiological Insights

Neuroendocrine Carcinoma Epidemiology Segmentation:

The Neuroendocrine Carcinoma market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

• Total Neuroendocrine Carcinoma Incident Cases
• Total Incident Cases of Extrapulmonary Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma Stage-specific Cases
• Neuroendocrine Carcinoma Site-specific Cases
• Neuroendocrine Carcinoma Gender-specific Cases
• Neuroendocrine Carcinoma Histology-specific Cases
• Total Neuroendocrine Carcinoma Treated Cases

Neuroendocrine Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Neuroendocrine Carcinoma market or expected to get launched during the study period. The analysis covers Neuroendocrine Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuroendocrine Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neuroendocrine Carcinoma Therapies and Key Companies

• Obrixtamig (BI 764532): Boehringer Ingelheim/Oxford BioTherapeutics
• Tarlatamab-dlle (IMDELLTRA): Amgen
• Zocilurtatug pelitecan (ZL-1310): Zai Lab/MediLink Therapeutics
• Gocatamig (MK-6070): Merck/Daiichi Sankyo
• Voyager-V1 in combination with pembrolizumab: Vyriad
• Peluntamig (PT217): Phanes Therapeutics
• Clesitamig (RO7616789): Roche

To know more about Neuroendocrine Carcinoma treatment, visit @ Neuroendocrine Carcinoma Medications

Neuroendocrine Carcinoma Market Drivers

• Increasing incidence of neuroendocrine malignancies and aggressive neuroendocrine tumors worldwide
• Advancements in diagnostic technologies, including improved imaging techniques, biomarker testing, PET scans, and molecular diagnostics enabling earlier and more accurate diagnosis
• Growing adoption of targeted therapies and precision medicine approaches improving treatment outcomes
• Expansion of immunotherapy applications, particularly immune checkpoint inhibitors and combination immunotherapies
• Strong pipeline of emerging therapies targeting tumor growth pathways and molecular alterations
• Increasing research and development investments in oncology research and rare cancer therapeutics
• Growing awareness among healthcare professionals and patients supporting timely diagnosis and treatment initiation
• Rising demand for personalized medicine and biomarker-driven therapies enhancing therapeutic effectiveness

Neuroendocrine Carcinoma Market Barriers

• Aggressive tumor biology and frequent late-stage diagnosis leading to poor prognosis
• High mortality rates and limited long-term survival outcomes
• Absence of disease-specific approved therapies, requiring reliance on off-label treatments
• Limited late-stage pipeline with most candidates in early Phase I/II development
• Delayed and complex diagnosis obscuring early identification of Neuroendocrine Carcinoma
• Variability in patient response and limited long-term efficacy of existing chemotherapy regimens
• High cost of advanced emerging therapies and potential reimbursement challenges
• Stringent regulatory requirements and lengthy approval timelines for novel oncology treatments
• Scarcity of specialized neuroendocrine oncology centers in certain regions

Scope of the Neuroendocrine Carcinoma Market Report

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Study Period: 2022-2036
• Key Neuroendocrine Carcinoma Companies: Boehringer Ingelheim, Oxford BioTherapeutics, Amgen, Zai Lab, MediLink Therapeutics, Merck, Daiichi Sankyo, Vyriad, Phanes Therapeutics, and others
• Key Neuroendocrine Carcinoma Therapies: Obrixtamig (BI 764532), Tarlatamab-dlle (IMDELLTRA), Zocilurtatug pelitecan (ZL-1310), Gocatamig (MK-6070), Voyager-V1 in combination with pembrolizumab, Peluntamig (PT217), and others
• Neuroendocrine Carcinoma Therapeutic Assessment: Current treatment landscape and emerging therapies
• Neuroendocrine Carcinoma Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, Porter’s five forces, market entry strategies
• Neuroendocrine Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

Kanishk

kkumar@delveinsight.com 

The healthcare technology consulting sector stands at a pivotal juncture, with organizations across the globe grappling with unprecedented digital transformation challenges. Market research indicates that the demand for specialized IT guidance has intensified significantly, particularly as healthcare providers navigate complex regulatory environments and evolving patient care paradigms.

Industry analysis reveals that healthcare institutions are increasingly dependent on external expertise to successfully deploy and manage sophisticated technology ecosystems. The surge in digital health initiatives, coupled with stringent compliance requirements, has created a robust market environment where specialized consulting services have become indispensable for sustainable growth and operational excellence.

The convergence of regulatory pressures, technological advancement, and cost containment imperatives has fundamentally altered how healthcare organizations approach their IT strategies. This shift has generated substantial opportunities for consulting professionals who can bridge the gap between clinical needs and technological capabilities.

Technological Integration and Implementation Strategies

Modern healthcare environments require sophisticated approaches to technology deployment and optimization. Healthcare IT Consulting Companies have evolved their methodologies to address increasingly complex integration challenges, particularly as organizations seek to harmonize legacy systems with cutting-edge digital solutions.

The implementation landscape has become significantly more nuanced, with consulting professionals developing specialized frameworks for managing large-scale digital transformations. These frameworks typically encompass comprehensive risk assessment, stakeholder alignment, and phased deployment strategies designed to minimize operational disruption while maximizing technology adoption rates.

Artificial intelligence and machine learning integration has emerged as a particularly challenging area requiring specialized expertise. Healthcare organizations are investing heavily in these technologies but often lack the internal capabilities necessary for successful implementation and ongoing optimization.

Service Delivery Models and Operational Frameworks

The evolution of service delivery approaches reflects the growing sophistication of healthcare IT requirements. Contemporary Healthcare IT Consulting Mechanism strategies emphasize agile methodologies, continuous improvement processes, and outcome-based performance metrics.

Consulting firms have developed innovative engagement models that combine traditional project-based approaches with ongoing advisory relationships. This hybrid model enables healthcare organizations to access specialized expertise while building internal capabilities over time.

The emphasis on data-driven decision making has fundamentally transformed how consulting services are delivered. Modern engagements typically involve comprehensive analytics capabilities, real-time performance monitoring, and predictive modeling to ensure optimal technology performance and return on investment.

Device Connectivity and Integration Challenges

The proliferation of connected medical technologies has created new consulting opportunities focused on device integration and data management. Healthcare IT Consulting Medical devices integration represents a rapidly expanding market segment as healthcare providers seek to leverage device-generated data for improved clinical outcomes.

Consulting professionals are addressing complex challenges related to device interoperability, data standardization, and clinical workflow integration. The regulatory environment surrounding connected medical devices continues to evolve, creating additional complexity that requires specialized expertise and ongoing guidance.

Remote monitoring capabilities and wearable technology integration have become particularly important focus areas. Healthcare organizations require sophisticated strategies for managing the volume and variety of data generated by these devices while ensuring appropriate clinical utilization and patient privacy protection.

Market Competition and Industry Positioning

The competitive environment features a diverse ecosystem of service providers ranging from global technology consultancies to specialized healthcare IT firms. Market leaders are differentiating themselves through deep industry expertise, innovative service delivery models, and strategic technology partnerships.

Consolidation trends continue to reshape the competitive landscape as larger firms acquire specialized capabilities and expand their geographic reach. This consolidation is driving increased specialization and the development of niche expertise areas within the broader consulting market.

Strategic partnerships between consulting firms and technology vendors have become increasingly important for maintaining competitive positioning. These relationships enable consulting providers to offer integrated solutions while technology vendors gain access to implementation expertise and market reach.

Forward-Looking Market Projections

Analytical projections for the Healthcare IT Consulting sector through 2034 indicate sustained growth driven by continued digital transformation initiatives and emerging technology adoption. Market expansion is expected to accelerate as healthcare organizations increasingly recognize the strategic value of specialized IT expertise.

Emerging opportunities in areas such as precision medicine, genomics integration, and advanced analytics are expected to drive demand for highly specialized consulting services. The growing emphasis on population health management and value-based care models will create additional market segments focused on data analytics and performance optimization.

Cybersecurity consulting is projected to experience particularly strong growth as healthcare organizations face increasing cyber threats and evolving regulatory requirements. The market is expected to see continued innovation in service delivery models and the development of specialized expertise areas that address specific healthcare IT challenges

Latest Reports Offered by Delveinsight

noonan syndrome market | klinefelter syndrome market | childhood atropine for myopia progression market | hiatal hernia market | laron syndrome market |onycholysis market | orthopedic splints device market | peripheral nerve repair devices market | plantar fasciitis market | rabies virus market |acute pulmonary embolism market | arteriovenous fistula market | global kinase inhibitor market | locally advanced pancreatic cancer market | retinal detachment disorder market |us healthcare outlook report | chronic wounds market | keratisis market | mccune-albright syndrome market | motor neuron disease market |penile cancer market | salivary gland infection market | surgical sealant market | surgical stapling devices market | urinary incontinence devices market |artificial kidney market | pulse oximeter market | urea cycle disorders market | car t cell therapy market | cerebral vein thrombosis market |drug hypersensitivity market | hypercoagulability market | pulmonary embolism market | antibody drug conjugate market | apheresis market |biliary tumor market | guillain-barré syndrome market | neuromodulation devices market | richter syndrome market | cervical intraepithelial neoplasia market |her3 market | nerve repair and regeneration devices market | oxygen concentrators market | undifferentiated pleomorphic sarcoma market | intraocular lymphoma market |car-t market | dental laser market | next generation immunotherapies market | reactive arthritis market | spinal implants market |

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com